Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?
出版年份 2021 全文链接
标题
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?
作者
关键词
-
出版物
CURRENT OPINION IN CARDIOLOGY
Volume 36, Issue 5, Pages 672-681
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2021-06-26
DOI
10.1097/hco.0000000000000892
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comprehensive Care Models for Cardiometabolic Disease
- (2021) Cara Reiter-Brennan et al. Current Cardiology Reports
- CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
- (2021) Michael McDonald et al. CANADIAN JOURNAL OF CARDIOLOGY
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States
- (2020) Sarah Naz Ali et al. ADVANCES IN THERAPY
- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
- (2020) Eileen O’Meara et al. CANADIAN JOURNAL OF CARDIOLOGY
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
- (2020) Abhinav Sharma et al. CIRCULATION
- Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
- (2020) Jeffrey I. Mechanick et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial
- (2020) Abhinav Sharma et al. Journal of the American Heart Association
- Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events
- (2020) Arsalan Hamid et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
- (2020) James Heyward et al. PLoS One
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
- (2020) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide
- (2020) Peter A. Senior et al. Canadian Journal of Diabetes
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes ( TRS‐HF DM ) in patients in the ACCORD trial
- (2020) Malik Elharram et al. DIABETES OBESITY & METABOLISM
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
- (2019) Emily Brown et al. DIABETES OBESITY & METABOLISM
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
- (2019) Suzanne V. Arnold et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- (2019) Aaron Y. Kluger et al. Cardiovascular Diabetology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Technology-Enabled Clinical Trials
- (2019) Guillaume Marquis-Gravel et al. CIRCULATION
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists’ attitudes and practice
- (2019) Thomas A Slater et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
- (2019) Abhinav Sharma et al. ESC Heart Failure
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease
- (2018) Kevin M. Pantalone et al. Cardiovascular Diabetology
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure
- (2018) Abhinav Sharma et al. Circulation-Heart Failure
- Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care
- (2018) Abhinav Sharma et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
- (2018) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- A systematic review of gamification in e-Health
- (2017) Lamyae Sardi et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes
- (2017) Yingying Yang et al. MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Status of Preventive Cardiology Training Among United States Cardiology Fellowships and Comparison to Training Guidelines
- (2012) Quinn R. Pack et al. AMERICAN JOURNAL OF CARDIOLOGY
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search